Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319027 · ClinicalTrials.gov registry record · Phase 2
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
A Phase 2 study of Glioblastoma, IDH-wildtype, sponsored by ECOG-ACRIN Cancer Research Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06319027: Recruiting Phase 2 study of Glioblastoma, IDH-wildtype, sponsored by ECOG-ACRIN Cancer Research Group.
NCT06319027 is a Phase 2 study of Glioblastoma, IDH-wildtype that is actively recruiting participants, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 100 participants, below the 271-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06319027, a Phase 2 study of Glioblastoma, IDH-wildtype, is actively recruiting participants, sponsored by ECOG-ACRIN Cancer Research Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.
Primary Outcome
Will use a two-sided log-rank test to compare the difference in OS between marker positive and marker negative participants using a significance level of 0.05.
Conditions Studied
Interventions
- PROCEDURE Positron Emission Tomography
- OTHER Fluciclovine F18
- PROCEDURE Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- DRUG Gadolinium-Chelate
- PROCEDURE Magnetic Resonance Spectroscopy
Study Locations (1)
Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
What NCT06319027 shows while recruiting
NCT06319027 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 271-participant average among 15 other Glioblastoma, IDH-wildtype trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Glioblastoma, IDH-wildtype appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.
NCT06319027 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06319027 about?
NCT06319027 is a clinical study titled "Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial". This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI)....
What is the current status of trial NCT06319027?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-04-11. Estimated completion is 2027-05-31.
What conditions does trial NCT06319027 study?
This clinical trial studies the following conditions: Glioblastoma, IDH-wildtype.
What interventions are being tested in trial NCT06319027?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Fluciclovine F18 (OTHER), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Gadolinium-Chelate (DRUG), Magnetic Resonance Spectroscopy (PROCEDURE).
Who is sponsoring clinical trial NCT06319027?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319027 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma, IDH-wildtype
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06319027's enrollment target sits among peer trials
100 9th of 15 higher than 7 of 15 other Glioblastoma, IDH-wildtype trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma, IDH-wildtype trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
ACTIVE NOT RECRUITING · Phase 2
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
-
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
RECRUITING
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI